Details

Autor(en) / Beteiligte

• Liu, Li-Ting, MD
• Tang, Lin-Quan, MD, PhD
• Chen, Qiu-Yan, MD, PhD
• Zhang, Lu, MD
• Guo, Shan-Shan, MD
• Guo, Ling, MD, PhD
• Mo, Hao-Yuan, MD, PhD
• Zhao, Chong, MD, PhD
• Guo, Xiang, MD, PhD
• Cao, Ka-Jia, MD, PhD
• Qian, Chao-Nan, MD, PhD
• Zeng, Mu-Sheng, MD, PhD
• Bei, Jin-Xin, MD, PhD
• Hong, Ming-Huang, MD, PhD
• Shao, Jian-Yong, MD, PhD
• Sun, Ying, MD, PhD
• Ma, Jun, MD, PhD
• Mai, Hai-Qiang, MD, PhD

Titel

The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma

Ist Teil von

• International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (4), p.862-869

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose To explore the prognostic value of the plasma load of Epstein-Barr viral (EBV) DNA and the tumor response to neoadjuvant chemotherapy (NACT) in advanced-stage nasopharyngeal carcinoma (NPC). Patients and Methods In all, 185 consecutive patients with stage III to IVb NPC treated with NACT followed by concurrent chemoradiation therapy (CCRT) were prospectively enrolled. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included locoregional relapse–free survival (LRFS) and distant metastasis–free survival (DMFS). Results EBV DNA was detected in 165 (89%) patients before treatment but was undetectable in 127 (69%) patients after NACT. Detectable EBV DNA levels after NACT were correlated with poor prognosis (3-year PFS 71.8% vs 85.2%, P =.008 and 3-year DMFS 82.5% vs 92.3%, P =.013). An unsatisfactory tumor response (stable disease or disease progression) after NACT was also correlated with poor clinical outcome (3-year PFS 71.1% vs 85.9%, P =.005 and 3-year LRFS 82.7% vs 93.5%, P =.012). Multivariate analysis showed that the EBV DNA level after NACT (hazard ratio [HR] 2.31, 95% CI 1.18-4.54, P =.015) and the tumor response to NACT (HR 2.84, 95% CI 1.42-5.67, P =.003) were both significant prognostic factors for PFS. Multivariate analysis also showed that EBV DNA after NACT was the only significant predictor of DMFS (HR 2.99, 95% CI 1.25-7.15, P =.014) and that tumor response to NACT was the only significant predictor of LRFS (HR 3.31, 95% CI 1.21-9.07, P =.020). Conclusion Detectable EBV DNA levels and an unsatisfactory tumor response (stable disease or disease progression) after NACT serve as predictors of poor prognosis for patients with advanced-stage NPC. These findings will facilitate further risk stratification, early treatment modification, or both before CCRT.